Literature DB >> 17201120

Endogenous expression of CD80 co-stimulatory molecule facilitates in vivo tumor regression of oral squamous carcinoma.

Giovana R Thomas1, Judy Wen.   

Abstract

BACKGROUND: Most tumor tissues, especially those of non-hematopoietic origin, do not express CD80 co-stimulatory molecules, possibly as a mechanism to evade immune surveillance. The objective of this study was to determine whether abundant endogenous CD80 expression on oral squamous cell carcinoma (SCC) early during tumor progression can facilitate immune elimination and reverse immune tolerance.
MATERIALS AND METHODS: The growth of regressor and progressor oral SCC lines with differing endogenous CD80 expression were examined in immune-competent and -deficient mice. Immune effectors were determined by T-cell depletion experiments and immunohistochemistry.
RESULTS: Our studies show regression of early tumor growth when immunocompetent animals are inoculated with oral SCC progressor cell lines expressing abundant endogenous CD80. The CD80-induced antitumor response was due largely to induced T-cell responses.
CONCLUSION: Our findings suggest that inadequate CD80 expression during early oral SCC formation may contribute to the escape of tumors from immune elimination. This information can be useful in the design of new approaches to generate more effective immunotherapy against this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201120

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers.

Authors:  Chiara Tuccilli; Enke Baldini; Salvatore Sorrenti; Antonio Catania; Alessandro Antonelli; Poupak Fallahi; Francesco Tartaglia; Susi Barollo; Caterina Mian; Andrea Palmieri; Giovanni Carbotta; Stefano Arcieri; Daniele Pironi; Massimo Vergine; Massimo Monti; Salvatore Ulisse
Journal:  Int J Endocrinol       Date:  2018-07-05       Impact factor: 3.257

2.  Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer.

Authors:  Nithya Sivaram; Patrick A McLaughlin; Han V Han; Oleksi Petrenko; Ya-Ping Jiang; Lisa M Ballou; Kien Pham; Chen Liu; Adrianus Wm van der Velden; Richard Z Lin
Journal:  J Clin Invest       Date:  2019-05-21       Impact factor: 19.456

3.  Expression of CD80 and CD86 costimulatory molecules are potential markers for better survival in nasopharyngeal carcinoma.

Authors:  Cheng-Shyong Chang; Julia H Chang; Nicholas C Hsu; Hsuan-Yu Lin; Chih-Yuan Chung
Journal:  BMC Cancer       Date:  2007-05-24       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.